Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|November 1, 2006
Alcon licenses anti-infective compound
Fort Worth, TX-Alcon Laboratories' affiliate Alcon Manufacturing Ltd. has signed a collaboration and licensing agreement with NovaCal Pharmaceuticals to research, develop, and commercialize NovaCal's novel Aganocide topical compounds to treat bacterial, viral, and fungal infections in the eye, ear, and sinus.
Advertisement
Fort Worth, TX-Alcon Laboratories' affiliate Alcon Manufacturing Ltd. has signed a collaboration and licensing agreement with NovaCal Pharmaceuticals to research, develop, and commercialize NovaCal's novel Aganocide topical compounds to treat bacterial, viral, and fungal infections in the eye, ear, and sinus.
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Comments from the FDA Advisory Committee meeting on SYD-101
2
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
3
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
4
FAQ: Diabetic eye disease awareness month 2026
5